Compassionate Use, Individual Patient access to velzatinib (GSK6042981) for eligible patients with Gastrointestinal Stromal Tumours (GIST) who have KIT mutations and at least three prior lines of therapy
There is no satisfactory alternative treatment for the patient including approved standard of care treatments for their diagnosis of Gastrointestinal Stromal Tumour (GIST)
There is reason to believe that the benefit of the patient using GSK6042981 (IDRX-42) outweighs the risk
Patient does not qualify for other ongoing clinical trials
Patient is diagnosed with Gastrointestinal Stromal Tumour (GIST) and positive for a KIT mutation (in one of exons 9, 11, 13, 17)
Patient has had at least 3 prior lines of therapy
Patient has adequate organ system function
Written informed consent can be obtained from the patient or legally authorized representative
Velzatinib (GSK6042981)
DrugClick on the lead sponsor to view all of their trials.
